期刊文献+

Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting 被引量:2

下载PDF
导出
摘要 Pediatric neuroblastomas(NBs)are heterogeneous,aggressive,therapy-resistant embryonal tumours that originate from cells of neural crest(NC)origin and in particular neuroblasts committed to the sympathoadrenal progenitor cell lineage.Therapeutic resistance,post-therapeutic relapse and subsequent metastatic NB progression are driven primarily by cancer stem cell(CSC)-like subpopulations,which through their self-renewing capacity,intermittent and slow cell cycles,drug-resistant and reversibly adaptive plastic phenotypes,represent the most important obstacle to improving therapeutic outcomes in unfavourable NBs.In this review,dedicated to NB CSCs and the prospects for their therapeutic eradication,we initiate with brief descriptions of the unique transient vertebrate embryonic NC structure and salient molecular protagonists involved NC induction,specification,epithelial to mesenchymal transition and migratory behaviour,in order to familiarise the reader with the embryonic cellular and molecular origins and background to NB.We follow this by introducing NB and the potential NC-derived stem/progenitor cell origins of NBs,before providing a comprehensive review of the salient molecules,signalling pathways,mechanisms,tumour microenvironmental and therapeutic conditions involved in promoting,selecting and maintaining NB CSC subpopulations,and that underpin their therapy-resistant,self-renewing metastatic behaviour.Finally,we review potential therapeutic strategies and future prospects for targeting and eradication of these bastions of NB therapeutic resistance,post-therapeutic relapse and metastatic progression.
出处 《World Journal of Stem Cells》 SCIE 2021年第7期685-736,共52页 世界干细胞杂志(英文版)(电子版)
  • 相关文献

参考文献2

二级参考文献110

  • 1[K] Wang JC, Dick JE. Cancer stem cells: lessons from leukemia.Trends Cell Biol 2005; 15: 494-501 [PMID: 16084092 DOI:10.1016/j.tcb.2005.07.004].
  • 2[K] Kreso A, Dick JE. Evolution of the cancer stem cell model.Cell Stem Cell 2014; 14: 275-291 [PMID: 24607403 DOI:10.1016/j.stem.2014.02.006].
  • 3[K] Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells,cancer, and cancer stem cells. Nature 2001; 414: 105-111 [PMID:11689955 DOI: 10.1038/35102167].
  • 4[K] Woll PS, Kj-llquist U, Chowdhury O, Doolittle H, Wedge DC,Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q,Mead AJ, Stenson L, Giustacchini A, Duarte S, GiannoulatouE, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T,Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P,Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, BowenD, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A,Vyas P, G-hring G, Schlegelberger B, Tobiasson M, KvalheimG, Constantinescu SN, Nerlov C, Nilsson L, CampbellPJ, Sandberg R, Papaemmanuil E, Hellstr-m-Lindberg E,Linnarsson S, Jacobsen SE. Myelodysplastic syndromes arepropagated by rare and distinct human cancer stem cellsin vivo. Cancer Cell 2014; 25: 794-808 [PMID: 24835589 DOI:10.1016/j.ccr.2014.03.036].
  • 5[K] Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, LaiTC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M.Cisplatin selects for multidrug-resistant CD133+ cells in lungadenocarcinoma by activating Notch signaling. Cancer Res2013; 73: 406-416 [PMID: 23135908 DOI: 10.1158/0008-5472.can-12-1733].
  • 6[K] Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN,Chen Z, Stowers PN, Courtney AN, Lakoma A, BarbieriE, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM. G-CSFreceptor positive neuroblastoma subpopulations are enrichedin chemotherapy-resistant or relapsed tumors and are highlytumorigenic. Cancer Res 2013; 73: 4134-4146 [PMID: 23687340DOI: 10.1158/0008-5472.can-12-4056].
  • 7[K] Jain S, Ward MM, O’Loughlin J, Boeck M, Wiener N, ChuangE, Cigler T, Moore A, Donovan D, Lam C, Cobham MV,Schneider S, Christos P, Baergen RN, Swistel A, Lane ME,Mittal V, Rafii S, Vahdat LT. Incremental increase in VEGFR1 - hematopoietic progenitor cells and VEGFR2- endothelialprogenitor cells predicts relapse and lack of tumor responsein breast cancer patients. Breast Cancer Res Treat 2012; 132:235-242 [PMID: 22160642 DOI: 10.1007/s10549-011-1906-3].
  • 8[K] Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM,Powers CN, Manjili MH. CD44(+)/CD24(-/low) cancerstem/progenitor cells are more abundant in triple-negativeinvasive breast carcinoma phenotype and are associated withpoor outcome. Hum Pathol 2012; 43: 364-373 [PMID: 21835433DOI: 10.1016/j.humpath.2011.05.005].
  • 9[K] Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C,Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y,Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, JonesC, Wakimoto H, Reynolds BA, Pallen CJ, Dunn SE. YB-1bridges neural stem cells and brain tumor-initiating cells viaits roles in differentiation and cell growth. Cancer Res 2011;71: 5569-5578 [PMID: 21730024 DOI: 10.1158/0008-5472.can-10-2805].
  • 10[K] Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, LiberD, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB,Brown R. Ovarian cancer stem cell-like side populations areenriched following chemotherapy and overexpress EZH2.Mol Cancer Ther 2011; 10: 325-335 [PMID: 21216927 DOI:10.1158/1535-7163.mct-10-0788].

共引文献8

同被引文献4

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部